Previous studies have highlighted the potential of bufalin in increasing the sensitivity of cancer cells to targeted therapy, particularly sorafenib in hepatocellular carcinoma [41–43] and MEKi in leukemia [44], as well as in reversing ABCB1-mediated resistance to docetaxel in breast cancer [58]. Here, ABCB1 is linked to breast carcinoma.